Is a 'Cure' for Blindness Worth $1 Million?
By Sarah Zhang,
The Atlantic
| 12. 27. 2017
Some blind people are questioning how the first gene therapy to treat inherited blindness has been valued.
Among blind people, says Kim Charlson, asking if you’d prefer to see always starts a lively debate: “Every opinion is going to be different.” Charlson, who lost her sight at age 11 and now is president of the American Council of the Blind, says she would hold out for full color vision. Others might settle for seeing in blurry black and white. And yet other blind people might have no desire to see at all.
For a small number of blind people, this hypothetical question recently become a real one.
Last week, the Food and Drug Administration approved Luxturna, the first gene therapy to treat a specific form of inherited blindness called Leber’s congenital amaurosis. In fact, it’s the first gene therapy to treat any inherited disease at all. The news has been universally hailed as a scientific breakthrough. But its stratospheric cost—potentially $1 million per patient—has provoked hard questions about the value of the ability to see, especially if its...
Related Articles
By Julie Métraux, Mother Jones | 09.23.2025
By Auriane Polge, Science & Vie [cites CGS' Katie Hasson] | 09.19.2025
L’idée de pouvoir choisir certaines caractéristiques de son futur enfant a longtemps relevé de la science-fiction ou du débat éthique. Aujourd’hui, les technologies de séquençage et les algorithmes d’analyse génétique repoussent les limites de ce qui semblait encore impossible. Au croisement...
By Dorian Accoe, BioNews | 09.15.2025
Many fertility clinics and gamete banks exclude candidate donors who are neurodivergent or have a family history of neurodivergence. Neurodivergence refers to a form of neurocognitive functioning that diverges from neurotypical or socially dominant norms, such as autism, attention deficit...
By Sayantani DasGupta, MedPage Today | 08.05.2025
It's just a jeans ad.
It's not that deep.
It's just social media outrage.
Should physicians care about the recent American Eagle "Sydney Sweeney Has Good Genes Jeans" controversy? What, if anything, does the provocative campaign have to...